European Psychiatry - Volume 33 - March 2016

114 / 812

S110 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115
Introduction Dysregulation of the apoptotic process is associ-
ated with the etiopathogenesis of schizophrenia, which is observed
at the brain and peripheral blood levels. A significant nega-
tive correlation between the duration of the disease and serum
sFasL concentration was demonstrated by other authors. It was
shown that an increased rate of apoptosis is more pronounced in
neuroleptic-free patients with the first-episode of schizophrenia
than in patients with chronic disease.
Aim Search for a predictor of good response to antipsychotic
treatment based on the analysis of the sFasL plasma level and its
relationship with clinical symptoms.
Methods Fifty-three patients with chronic schizophrenia and 46
healthy individualswere enrolled in the study. The concentration of
sFasL was measured by ELISA. Clinical assessments (PANSS, SANS,
SAPS) and blood analyses were conducted three times: during the
active phase of disease (at admission), after 4 weeks of pharma-
cotherapy, and after reaching remission.
Results In the schizophrenia group, non-altered levels of sFasL
(P = 0.1; U Mann-Whitney test), compared to the control, were
detected at admission. The initial level of sFasL correlated nega-
tively (r= −0.33; P = 0.04; Spearman’s rank) with blood leukocyte
count. Despite clinical improvement, no significant changes in the
level of sFasL were observed. However, the sFasL level correlated
negatively with the PANSS general psychopathology reduction
after 4 weeks of pharmacotherapy ( r= −0.7; P = 0.04) and after
remission (r = −0.39; P = 0.026).
Conclusions The results indicate a possible role of sFasL in apo-
ptosis of blood leukocytes and suggest that the reduction of sFasL
level can predict level of PANSS general psychopathology after
antipsychotic treatment in schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC93
Basic symptoms as subjective
cognitive deficit in schizophrenia:
Cognitive, clinical and functional
associations
M.L. Vargas ∗, S. López-Lorenzo , I. Legascue , A. Nagore ,
P. Serrano , N. Jimeno-Bulnes
1 Complejo Asistencial de Segovia, Grupo de Investigación en
Neurociencia Clínica de Segovia GINCS, Psychiatry, Segovia, Spain
2 Grupo de Investigación en Neurociencia Clínica de Segovia GINCS,
Psychiatry, Segovia, Spain
3 Universidad de Valladolid, Grupo de Investigación en Neurociencia
Clínica de Segovia GINCS, Psychiatry, Segovia, Spain
∗ Corresponding author.
Introduction Basic symptoms are subjective complaints that
present at the early states in psychotic disorders and persist in the
long-term. They can be studied using hetero applied clinical instru-
ments or self-administered questionnaires. Basic symptoms can be
useful as screening tools in at risk populations.
Aims To determine if basic symptoms (subjective cognitive
deficits) are associated with the objectively measured cognitive
deficit after controlling for functioning and symptomatology.
Methods One observational, transversal, psychopathological and
neuropsychological study was performed on a schizophrenia out-
patients sample (n = 78). Correlations were measured by using
Spearman’s Rho coefficient. Basic symptoms were registered by
using the Frankfurt Complaints Questionnaire (FCQ-3); cognitive
status was assessed by Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS); clinical status was assessed
by PANSS and Clinical Global Impression (CGI); functional status
was measured with Global Assessment of Functioning (GAF).
Results All the dimensionswere related to subjective complaints:
cognitive functioning (r = −.38; P < .001); positive symptoms
(r = .54; P < .001); negative symptoms (r = .26; P< .02); general
symptoms (r= .41; P < .001); CGI (r = .57; P < .001); GAF (r = −.45;
P < .001). The association between subjective and objective cogni-
tive deficit remains significative after controlling for the clinical and
functional variables, except when controlling for CGI.
Conclusions The evaluation of basic symptoms with FCQ-3 is
related with an objective cognitive deficit and could be useful as
a screening tool.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC94
Adjunctive memantine in
clozapine-treated refractory
schizophrenia: A one-year extension
study
S. Veerman ∗, P. Schulte , J.B. Deijen , L. de Haan
1 Mental Health Service Organisation North Holland North,
Community Mental Health Division, Flexible Assertive Community
Treatment, Alkmaar, Netherlands
2 Mental Health Service Organisation North Holland North, Division
for Specialised Treatment, Treatment Centre for Bipolar Disorders,
Alkmaar, Netherlands
3 VU Medical Center, Psychology, Amsterdam, Netherlands
4 Academic Medical Center, University of Amsterdam, Academic
Psychiatric Centre, Early Psychosis Department, Arkin, Amsterdam,
Netherlands
∗ Corresponding author.
Introduction In a recent 26-week placebo-controlled, crossover
trial (n = 52) we found significant positive effects on verbal and
visual memory, and negative symptoms in clozapine-treated
patients with refractory schizophrenia.
Objectives In this 1-year extension study, we report the long-
term effects and tolerability of memantine add-on therapy to
clozapine.
Aims To evaluate the persistence of improvements in cognitive
functioning and symptoms of memantine add-on therapy to cloza-
pine in schizophrenia.
Methods Completers of the first trial who experienced a bene-
ficial effect of memantine after 12 weeks continued memantine
for one year. Primary endpoints were change from baseline to 26
weeks treatment and 26 weeks to 52 weeks treatment on memory
and executive function using the Cambridge Neuropsychological
Test Automated Battery (CANTAB), Positive andNegative Syndrome
Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-
S). Secondary endpoints were change on the Health of the Nation
Outcome Scales (HoNOS) and Liverpool University Neuroleptic Side
Effect Rating Scale (LUNSERS).
Results Of 32 completers who experienced a beneficial effect
of memantine 23 patients continued memantine for one year.
Memory improvement was sustained, verbal recognition mem-
ory improved even further between t = 26 weeks and t = 52 weeks.
Continued treatment with memantine add-on to clozapine was
associated with significantly improved PANSS positive, negative
and overall score, CGI-S and HoNOS scores.
Conclusions In the extension phase the positive effect of
memantine add-on therapy on verbal memory sustained and pos-
itive, negative and overall symptoms of schizophrenia, clinical
global status and psychosocial functioning significantly improved.
Memantine was well tolerated without serious adverse effects.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.